New leadership and recapitalization to accelerate commercialization of proprietary silicon nitride technologies in medical and high-growth markets SALT LAKE CITY, Utah, June 12, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), the only FDA-registered producer of implantable silicon nitride and a global leader in advanced ceramics, today announced a renewed corporate vision and strategic plan to accelerate commercialization and unlock the full value of its intellec ...

Investor Presentation Second Quarter Equity Conferences Regulatory and Environmental Risks The Company's business is subject to extensive environmental laws, regulations and permits that may materially restrict or adversely affect how the Company conducts business and its financial results. The potential long-term impact of climate-related risks remain uncertain at this time. Regulatory measures to address climate change may materially restrict how the Company conducts business or adversely affect its finan ...

Rayonier Advanced Materials (RYAM) Update Summary Company Overview - Rayonier Advanced Materials (RYAM) is undergoing a transformation to separate its high-margin cellulose specialties (CS) business from lower-margin commodity exposure, while also highlighting its emerging biomaterials platform [1][2] Key Points and Arguments - **New Segment Reporting**: The company has updated its reporting structure to better reflect its current operations and to provide clearer visibility into its high-margin segments [1][2][10] - **Long-term Strategy**: Confidence in the long-term strategy and value creation plan remains unchanged despite recent operational challenges and market noise [2][4] - **Operational Challenges**: The recent quarter faced challenges including higher input costs, operational difficulties, and weather-related disruptions, but these do not alter the company's long-term fundamentals [3][4] - **Price Increases**: The CS business outlook is strong, with a mid-single-digit price increase secured for 2025 while maintaining market share [5][16] - **Market Position**: RYAM holds approximately 40% market share in cellulose specialties, producing both hardwoods and softwoods, which provides a competitive advantage [6] - **Maintenance and Efficiency**: Major maintenance shutdowns have been completed, and the company is focusing on efficiency gains and strategic capital deployment to enhance margins [6][8] - **Biomaterials Growth**: The biomaterials platform is positioned to benefit from growing demand for renewable materials, with investments supported by secured green financing [7][8][23] - **EBITDA Targets**: The company aims for an annual EBITDA target of $325 million, with a focus on execution of its strategy [8] Financial Performance - **EBITDA Margins**: The CS segment reported a 23% EBITDA margin, while the emerging biomaterials segment achieved a 29% EBITDA margin, indicating strong profitability in these areas [11][23] - **Sales and Guidance**: For 2025, guidance for the CS business is set between $237 million to $245 million, with earnings expected to be back-end loaded due to operational recovery [18][25] - **Overall Guidance**: The overall EBITDA guidance has been adjusted to $175 million to $185 million, reflecting challenges in non-core segments and tariff impacts [25] Competitive Landscape - **Cellulose Specialties**: This segment is crucial, accounting for 56% of sales volumes, and competes on performance with a long qualification process for products [16][17] - **Commodity Products**: The company is minimizing exposure to lower-margin commodity products, focusing instead on higher-value offerings [20][21] Strategic Initiatives - **Joint Venture with BioNova**: The creation of BioNova aims to accelerate growth in biomaterials while avoiding shareholder dilution, leveraging project-specific funding [29][30] - **Capital Allocation**: RYAM plans to generate $5 million to $15 million in free cash flow for strategic investments, with a focus on maintaining a healthy balance sheet [37][40] Macro Trends and Risks - **Tailwinds**: Strong demand for sustainable materials and favorable green funding environments are expected to benefit RYAM's operations [47] - **Risks**: Trade policy uncertainty, inflation in raw materials, and logistics challenges are potential risks that could impact performance [48][49] Conclusion - RYAM is positioned for growth through strategic focus on high-margin segments and investments in biomaterials, while navigating operational challenges and market dynamics. The company remains committed to executing its long-term strategy and achieving its financial targets [8][51]

PALM BEACH GARDENS, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced management will participate in the upcoming Stifel 2025 Jaws & Paws Conference. Management will be presenting on Wednesday, May 28, 2025 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time. A live webcast of the event, as well as an archived recording will be available on ZimVie’s investor website at investor.zimvie.com. About ZimVieZimVie is a global lif ...

Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financ ...

Rayonier Advanced Materials (RYAM) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Company Participants Mickey Walsh - VP of Investor Relations & TreasurerDe Lyle Bloomquist - President, CEO & DirectorMarcus Moeltner - CFO & Senior VP of FinanceMatt McKellar - Vice President Conference Call Participants Daniel Harriman - AnalystDmitry Silversteyn - Senior Research Analyst Operator Morning, and welcome to the Ryan First Quarter twenty twenty five Earnings Conference Call. As a reminder, this conference is bei ...

Financial Performance and Key Metrics - In Q1 2025, the company reported an 8% decline in revenue and a 67% reduction in adjusted EBITDA compared to Q1 2024, which was described as disappointing [5][9] - The company ended the quarter with liquidity of $272 million and a net secured debt reduction of $624 million, resulting in a net secured leverage ratio of 2.9 times covenant EBITDA [8][14] Business Segment Performance - In the Cellular Specialty segment, quarterly net sales decreased by $5 million to $201 million, with a 2% sales price increase offset by a 2% decline in sales volume [9][10] - The cellulose commodities segment saw net sales decline by $19 million to $75 million, with operating results improving by $6 million year over year to a loss of $13 million [10][11] - The new biomaterials segment maintained steady net sales at $7 million, with operating income flat at $2 million [11] - Paperboard segment net sales decreased by $4 million to $49 million, reflecting a 4% decrease in sales prices and a 3% decline in sales volumes [12] - High yield pulp segment net sales declined by $3 million to $31 million, with operating losses increasing to $7 million [12][13] Market Dynamics - The company faces significant challenges from tariffs, particularly a 25% tariff imposed by China on US-sourced cellulose commodities, affecting approximately $85 million of annual revenue [7][9] - The company is actively mitigating tariff risks through customer advocacy, market diversification, and operational adjustments [17][20] Strategic Direction and Industry Competition - The company plans to focus on tariff mitigation actions and will likely pause some strategic initiatives, including debt reduction, due to cash flow uncertainties [18][29] - The biomaterials growth strategy remains intact, with expectations for continued investment in US-centric projects [18][29] Management Commentary on Operating Environment and Future Outlook - Management acknowledged the challenging start to 2025 and ongoing uncertainties in the global market but expressed confidence in the resilience of the core business [74][75] - Adjusted EBITDA guidance for 2025 has been lowered to a range of $175 million to $185 million, reflecting various challenges including tariff impacts and production issues [21][22] Other Important Information - The company expects to see a modest improvement in paperboard volumes due to better market access within North America, although prices remain under pressure [27][50] - Corporate costs are projected to increase year over year, primarily due to a non-cash environmental reserve charge and foreign exchange headwinds [28] Q&A Session Summary Question: Conditions in the fluff pulp market with China's retaliatory tariffs - Management indicated that some Chinese customers continue to place orders but do not expect to absorb tariffs long-term, leading to a pivot towards non-tariff markets like India and Africa [31][34] Question: Evolution of volumes following Liberation Day - Management noted that volumes were lower than expected due to pre-orders and that orders resumed in May after a pause in April, with expectations for normalization by Q3 [39][43] Question: Evolution of paperboard guidance for 2025 - Management confirmed that the risk of tariffs on paperboard has reversed, and pricing is expected to decrease by approximately 5% due to increased supply [45][50]

First Quarter 2025 Financial Presentation Materials May 7, 2025 Safe Harbor Forward-Looking Statements Certain statements in this document regarding anticipated financial, business, legal or other outcomes, including business and market conditions, outlook and other similar statements relating to future events, developments or financial or operational performance or results, are "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 a ...

MiMedx (MDXG) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this developer of biomaterials made from sterilized human amniotic membrane would post earnings of $0.07 per share when it actually produced earnings of $0.07, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estima ...

Borregaard’s operating revenues increased to NOK 2,036 million (NOK 1,975 million)2 in the 1st quarter of 2025. EBITDA1 reached NOK 511 million (NOK 442 million). The result in BioSolutions increased, BioMaterials had a result in line with the corresponding quarter last year and Fine Chemicals had a lower result. Strong sales to agriculture were the main reason for the all-time high result in BioSolutions. For BioMaterials, higher sales prices were offset by lower sales volume, increased wood costs, and cos ...